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receiving antithrombotic therapy. However, the use of VKA was not optimal in elderly
patients and better prophylactic strategies may be warranted for them .
1129-217 A Decision-Tree Model Comparing First-Line Electrical 
Cardioversion to Ibutilide With or Without Magnesium 
Prophylaxis in the Treatment of Atrial Fibrillation
Craig I. Coleman, James S. Kalus, C. Michael White, Jeffrey Kluger, University of 
Connecticut, Storrs, CT, Hartford Hospital, Hartford, CT
Background: Ibutilide is cost-effective when compared to first-line electrical cardiover-
sion (EC) for atrial fibrillation (AF); however, these results are sensitive to alterations in
conversion rate. Prophylactic magnesium augments the efficacy of ibutilide as demon-
strated by an increased rate of successful conversion. The objective of this evaluation
was to compare the costs associated with first-line EC and ibutilide in the presence and
absence of magnesium prophylaxis for the conversion of AF. Methods: A decision-tree
model was developed to estimate the cost-effectiveness of first-line EC compared to
ibutilide with or without prophylactic intravenous magnesium sulfate followed by EC in
those patients who do not convert. Conversion rates for patients receiving ibutilide with or
without magnesium were based upon results of a multi-center, retrospective, cohort
study (n=319). Healthcare utilization costs including drugs, intravenous admixture and
administration, EC, electrocardiographs and physicians’ fees were based upon actual
costs from our institution. Cost-effectiveness was calculated by multiplying the cost of a
successful and unsuccessful outcome by their probability of occurrence and then adding
these two figures to determine total cost. Results: Ibutilide+magnesium was found to be
the most cost-effective for conversion of AF (see figure). Conclusion: The decision-tree
model suggests that ibutilide+magnesium is more cost-effective than ibutilide alone or
first-line EC. 
1129-218 Ibutilide Improves Cardioversion Success Rates in 
Patients on Chronic Amiodarone Therapy With 
Persistent Atrial Fibrillation
Jenny C. Hu, Kelly Machuca, Shelley DePeralta, Bramah Singh, Zenaida Feliciano, VA 
Greater Los Angeles Healthcare System, Los Angeles, CA
Background: Atrial fibrillation (AF) is the most common arrhythmia, affecting approxi-
mately 2.2 million people in the United States. A combination of amiodarone and ibutilide
has been used with results suggesting an additive or synergistic effect on AF conversion.
Methods: We retrospectively studied 90 consecutive patients with persistent AF receiv-
ing oral amiodarone therapy who elected for electrical cardioversion. Patients underwent
either direct current cardioversion (DCC) (Group A, n=67) or DCC with ibutilide pretreat-
ment (Group B, n=23). To evaluate the effect of AF duration on DCC success rate,
patients were further divided into AF duration < 1 year (Group A1, n=30 and Group B1,
n=4) and AF duration > 1 year (Group A2, n=37 and Group B2, n=19). Chi-square analy-
sis was used to evaluate the statistical significance (set at p<0.05) between groups.
Results:
All patients were male, mostly hypertensive (86%) and age 64 ± 9.6 years, body mass
index 34 ± 8.1 kg/m2, left atrial size 52 ± 8.4 mm, ejection fraction 52 ± 10 %, and AF
duration 2.8 years ± 3.1 years. DCC success rates were 60% in Group A and 87% in
Group B (p=0.02). A trend for DCC success rate improvement with ibutilide was seen in
patients with AF duration > 1 year (Group A2=57% vs. Group B2=84%, p=0.07). One
patient in the ibutilide pretreatment group developed torsade de pointes.
Conclusion: Ibutilide pretreatment for DCC may be a safe and effective method of
improving DCC success rates in patients with long duration persistent AF receiving amio-
darone therapy. 
POSTER SESSION
1130 
Channelopathies and Idiopathic 
Ventricular Tachycardia
Tuesday, March 09, 2004, 9:00 a.m.-11:00 a.m.
Morial Convention Center, Hall G
Presentation Hour: 10:00 a.m.-11:00 a.m.
1130-207 Prevalence and Spectrum of Mutations in the Cardiac 
Ryanodine Receptor in Patients Referred for Long QT 
Syndrome Genetic Testing
Laura J. Kopplin, David J. Tester, Michael J. Ackerman, Mayo Clinic, Rochester, MN
Background: Pathogenic mutations in the gene, RYR2, encoding the cardiac ryanodine
receptor cause type 1 catecholaminergic polymorphic ventricular tachycardia (CPVT1).
There is phenotypic overlap between the clinical presentation of CPVT and long QT syn-
drome (LQTS). Because the diagnosis of CPVT can be elusive, we sought to determine
the spectrum and prevalence of RYR2 mutations in a cohort of unrelated patients
referred specifically for LQTS genetic testing.
Methods: Since 1997, nearly 500 unrelated patients have been referred to Mayo Clinic’s
Sudden Death Genomics Laboratory for LQTS genetic testing. Putative pathogenic
mutations in the known LQTS-causing genes have been identified in approximately 50%
of the cases. Mutational analysis of 18 exons of RYR2 previously implicated in CPVT was
performed on genomic DNA from 240 genotype-negative subjects using polymerase
chain reaction, denaturing high performance liquid chromatography, and direct DNA
sequencing.
Results: Seventeen distinct RYR2 mutations (16 missense, 1 duplication insertion, 15
novel) were found in 20 out of 240 genotype-negative subjects (8.3%). None of these
mutations were present in 400 reference alleles. Two mutations localized to the
FKBP12.6 binding domain. Upon review of the clinical records, the referral diagnosis for
19 out of 20 patients was “atypical” or “borderline” LQTS rather than CPVT. None of the
individuals displayed diagnostic QT prolongation (QTc > 470 ms).
Conclusion: Putative pathogenic CPVT1-causing mutations in RYR2 were detected in
nearly 10% of unrelated and LQTS genotype-negative patients who were referred for
LQTS genetic testing. These findings suggest that CPVT may be under-recognized
among physicians referring patients with a suspected channelopathy. A diagnosis of
“atypical LQTS” may warrant consideration of CPVT and analysis of RYR2 if the primary
LQTS-causing channel screen is negative.
1130-208 Diagnostic Value of the Ajmaline Test Based on the 
Gene Analysis in Concealed Brugada Syndrome
Kui Hong, Kiyotaka Matsuo, Antonio Berruezo Sanchez, Matteo Vatta, Jeff Towbin, Josep 
Brugada, Pedro Brugada, Carlos Piñero Galvez, Charles Antzelevitch, Ramon Brugada, 
Masonic Medical Research Laboratory, Utica, NY
Background Brugada syndrome is an arrhythmogenic disease caused in part by muta-
tions in the cardiac sodium channel gene, SCN5A. The electrocardiogram in Brugada
syndrome is variable over time up to the point of normalization in some individuals. Diag-
nosis of possible affected individuals is performed with the use of sodium channel-block-
ing agents which unmask the EKG abnormality. However, validation of the testing has not
been performed. The use of genetic data as a gold standard in large families allows to
examine the effectiveness of ajmaline for diagnosis.
Methods We collected 4 large families with a total of 128 members. Ninety members
were relatives at possible risk of Brugada syndrome. Sixteen had a positive EKG at base-
